Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
200 hedge funds and large institutions have $1.23B invested in Sage Therapeutics in 2023 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 45 increasing their positions, 78 reducing their positions, and 31 closing their positions.
99% more call options, than puts
Call options by funds: $14.9M | Put options by funds: $7.46M
29% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 31
4% more funds holding
Funds holding: 193 → 200 (+7)
2% more capital invested
Capital invested by funds: $1.21B → $1.23B (+$25M)
3.25% less ownership
Funds ownership: 98.17% → 94.92% (-3.3%)
42% less repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 78
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$26.6M |
| 2 |
Morgan Stanley
New York
|
+$17.4M |
| 3 |
BlackRock
New York
|
+$8.86M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$6.97M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
+$6.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$43.9M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$22.5M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$10.9M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$10.1M |
| 5 |
State Street
Boston,
Massachusetts
|
-$9.12M |
SAGE Hedge Fund Activity: Q4 2023 in Review
200 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q4 2023, worth a combined $1.23B — up 2.1% from $1.21B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new SAGE positions and 31 closed out — a net gain of 9 holders — while 45 added to existing stakes and 78 trimmed.
The largest buyer was Cowen and Company, opening a new position worth an estimated $26.6M. The largest seller was Fidelity Investments, cutting an estimated $43.9M.
- 200 institutional investors held Sage Therapeutics (SAGE) as of Q4 2023, up from 193 in Q3 2023.
- Funds reported $1.23B of Sage Therapeutics stock for Q4 2023, up 2.1% quarter-over-quarter.
- 40 funds opened new Sage Therapeutics positions in Q4 2023 and 31 closed out, a net change of +9 holders.
- The largest Sage Therapeutics buyer in Q4 2023 was Cowen and Company, an estimated $26.6M added.
- The largest Sage Therapeutics seller in Q4 2023 was Fidelity Investments, an estimated $43.9M sold.
Based on aggregated 13F filings for Q4 2023.